These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25818479)

  • 1. Gene therapy for heart failure.
    Greenberg B
    J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
    Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
    JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
    Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
    Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
    Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
    Hulot JS; Salem JE; Redheuil A; Collet JP; Varnous S; Jourdain P; Logeart D; Gandjbakhch E; Bernard C; Hatem SN; Isnard R; Cluzel P; Le Feuvre C; Leprince P; Hammoudi N; Lemoine FM; Klatzmann D; Vicaut E; Komajda M; Montalescot G; Lompré AM; Hajjar RJ;
    Eur J Heart Fail; 2017 Nov; 19(11):1534-1541. PubMed ID: 28393439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
    Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
    Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.
    Samuel TJ; Rosenberry RP; Lee S; Pan Z
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.
    Hajjar RJ; Zsebo K; Deckelbaum L; Thompson C; Rudy J; Yaroshinsky A; Ly H; Kawase Y; Wagner K; Borow K; Jaski B; London B; Greenberg B; Pauly DF; Patten R; Starling R; Mancini D; Jessup M
    J Card Fail; 2008 Jun; 14(5):355-67. PubMed ID: 18514926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.
    Gwathmey JK; Yerevanian A; Hajjar RJ
    Hum Gene Ther; 2013 Nov; 24(11):937-47. PubMed ID: 24164241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.
    Lyon AR; Babalis D; Morley-Smith AC; Hedger M; Suarez Barrientos A; Foldes G; Couch LS; Chowdhury RA; Tzortzis KN; Peters NS; Rog-Zielinska EA; Yang HY; Welch S; Bowles CT; Rahman Haley S; Bell AR; Rice A; Sasikaran T; Johnson NA; Falaschetti E; Parameshwar J; Lewis C; Tsui S; Simon A; Pepper J; Rudy JJ; Zsebo KM; Macleod KT; Terracciano CM; Hajjar RJ; Banner N; Harding SE
    Gene Ther; 2020 Dec; 27(12):579-590. PubMed ID: 32669717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats].
    Hui HP; Li XY; Liu XH; Sun S; Lu XC; Liu T; Yang W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Apr; 34(4):357-62. PubMed ID: 16776934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.
    del Monte F; Williams E; Lebeche D; Schmidt U; Rosenzweig A; Gwathmey JK; Lewandowski ED; Hajjar RJ
    Circulation; 2001 Sep; 104(12):1424-9. PubMed ID: 11560860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.
    Lipskaia L; Chemaly ER; Hadri L; Lompre AM; Hajjar RJ
    Expert Opin Biol Ther; 2010 Jan; 10(1):29-41. PubMed ID: 20078230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure.
    Mattila M; Koskenvuo J; Söderström M; Eerola K; Savontaus M
    J Gene Med; 2016 Jul; 18(7):124-33. PubMed ID: 27203155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart.
    Cutler MJ; Wan X; Plummer BN; Liu H; Deschenes I; Laurita KR; Hajjar RJ; Rosenbaum DS
    Circulation; 2012 Oct; 126(17):2095-104. PubMed ID: 23019291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.
    Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R
    Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in gene therapy for heart failure.
    Fish KM; Ishikawa K
    Discov Med; 2015 Apr; 19(105):285-91. PubMed ID: 25977191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
    Zhai Y; Luo Y; Wu P; Li D
    J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered sarco(endo)plasmic reticulum calcium adenosine triphosphatase 2a content: Targets for heart failure therapy.
    Liu G; Li SQ; Hu PP; Tong XY
    Diab Vasc Dis Res; 2018 Jul; 15(4):322-335. PubMed ID: 29762054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
    Papolos A; Frishman WH
    Cardiol Rev; 2013; 21(3):151-4. PubMed ID: 23568057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.